secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001628280-25-008691
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex amends CEO Fried's contract to $650k base, grants 1.5M PSUs with $15-$50 stock price targets
--------------------------------------------------------------------------------

- Base salary increased to $650,000 effective Jan 1, 2025; target bonus raised to 75% of base for FY2025.
- CEO granted 1,518,600 PSUs with 7-year performance period; vest at stock price thresholds of $15, $20, $30, $40, $50.
- First tranche (759,300 PSUs) vests at $15 VWAP for 60 trading days; subsequent 189,825 each at higher thresholds.
- PSUs subject to five-year transfer restriction after vesting; no cash-out feature; forfeiture if targets not met by 2032.
- Under termination without cause or for good reason, unvested PSUs remain eligible for 12 months; transfer restrictions lapse.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025008691/0001628280-25-008691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828025008691/cdxc-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer